Pharmacokinetics of a potential antiepileptic drug GIZh-298
https://doi.org/10.37489/2587-7836-2024-2-57-61
EDN: GCFORG
Abstract
GIZh-298 pharmacokinetics was studied in rats after different dosage regimens.
The aim of this study was to study GIZh-298 pharmacokinetics after its multiple intragastric administration.
Methods. The study was conducted on outbred male rats. The concentrations of GIZh-298 in the blood plasma were determined by HPLC with mass-spectrometric detection. Pharmacokinetic parameters were evaluated using a model-independent method.
Results. After single and multiple (4 times with a dosage interval of 3 hours) intragastric administrations at 60 mg/kg dose, the test substance in the blood plasma was determined for 4 hours. The mode of administration of GIZh-298 did not affect the value of its half-life and the mean residence time. It has been established that GIZh-298 accumulates in the rats.
About the Authors
G. B. Kolyvanov
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Gennady B. Kolyvanov, PhD, Dr. Sci. (Biology), Leading Researcher of Laboratory of Pharmacokinetics
Moscow
A. A. Litvin
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Alexander A. Litvin, PhD, Dr. Sci. (Biology), Leading Researcher of Laboratory of Pharmacokinetics
Moscow
O. Yu. Kravtsova
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Oxana Yu. Kravtsova, PhD, Cand. Sci. (Biology), Leading Researcher of Laboratory of Pharmacokinetics
Moscow
O. G. Gribakina
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Oxana G. Gribakina, PhD, Cand. Sci. (Biology), Senior Research Scientist of the Laboratory of Pharmacokinetics
Moscow
V. P. Zherdev
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Vladimir P. Zherdev, PhD, Dr. Sci. (Med.), professor, Head of laboratory pharmacokinetics
Moscow
References
1. Mensah J.A., Johnson K, Reilly C.A., et al. Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. Epilepsia. 2022 Nov;63(11):2937-2948. doi: 10.1111/epi.17402.
2. Patent RU 2643091 C2/31.01.2018. Byul. №4 Durnev A.D., Voronina T.A., Litvinova S.A., et al. 4-Benzoylpyridine oxime derivatives having anticonvulsant activity as agents for treatment of epilepsy and paroxysmal states. (In Russ.). Доступно по: https://patents.s3.yandex.net/RU2643091C2_20180131.pdf. Ссылка активна на 24.05.2024.
3. Zhmurenko L.A., Mokrov G.V., Nerobkova L.N., et al. Novel 4-benzoylpyridine oxime derivative GIZH-298 with aticonvulsant activity. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2017;(1):22-26. (In Russ.).
4. Gaydukov I.O., Litvinova S.A., Voronina T.A., et al. 4-Benzoylpyridine oxime derivative (GIZH-298) versus valproic acid: the anticonvulsant potential effect in a model of epilepsy in rats with cobalt-induced lesions. Epilepsy and paroxysmal conditions. [Epilepsiya i paroksizmal’nye sostoyaniya] 2017;9(2):57-66 (In Russ.). doi: 10.17749/2077-8333.2017.9.2.057-066.
5. Guidelines for conducting preclinical studies of drugs. Part one. Metodicheskie rekomendacii po provedeniyu doklinicheskih issledovanij farmakokinetiki novyh lekarstvennyh sredstv. Mironov A.N. (ed.). Moscow: Grif and K, 2012. P. 865-880. (In Russ.). Доступно по: https://clck.ru/3BEMMg. Ссылка активна на 24.05.2024.
6. Gribakina O.G., Kravtsova O.Yu., Litvin A.A., et al. Pharmacokinetics of the potential pharmacological substance GIZh-298 in rats. Exper and Clin pharmacol. 2023;86(5):40-44. (In Russ.). doi: 10.30906/0869-2092-2023-86-5-40-44.
7. Sergienko V.I., Gelliff R., Bondareva I.B.; RAMN. Prikladnaya farmakokinetika: osnovnye polozheniya i klinicheskoe primenenie. Moscow: Izdatelstvo RAMN, 2003. (In Russ.). ISBN 5790100317.
8. Bochkov P.O., Kravtsova O.Yu., Kolyvanov G.B., Litvin A.A., Boyko S.S., Zherdev V.P. Quantification of a potential anticonvulsant drug GIZh-298 in rat plasma by liquid chromatography–mass spectrometry. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2022;(3):37–45. (In Russ.). doi: 10.37489/2587-7836-2022-3-37-45.
9. Farmacokinetika. Karkishenko N.N., Khoronko V.V., Sergeeva S.A., Karkishenko V.N.; Ed by Dolzhich GI. Rostov-na-Donu : Fenix, 2001. (In Russ.). ISBN 5-222-01504-1.
10. Osnovy farmacokinetiki. Miroshnichenko I.I. Moscow: Geotar-Med, 2002 (In Russ.). ISBN 5-9231-0211-0.
11. Tsaioun K. (ed), Kate S.A. (ed). ADMET for medicinal chemists: a practical guide. John Wiley & Sons, Inc., Hoboken, New Jersey, 2011. ISBN: 978-0-470-48407-4.
12. Vogel H.G., Maas J., Gebauer A. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer Verlag, Berlin, Heidelberg, 2011. ISBN 9783540898924. doi: 10.1007/9783540898917. Доступно по: http://ndl.ethernet.edu.et/bitstream/123456789/48230/1/Hans%20Gerhard%20Vogel.pdf. Ссылка активна на 24.05.2024.
Review
For citations:
Kolyvanov G.B., Litvin A.A., Kravtsova O.Yu., Gribakina O.G., Zherdev V.P. Pharmacokinetics of a potential antiepileptic drug GIZh-298. Pharmacokinetics and Pharmacodynamics. 2024;(2):57-61. (In Russ.) https://doi.org/10.37489/2587-7836-2024-2-57-61. EDN: GCFORG
Views:
237
Email this article 